1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment
of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-99. 2 …

Hepatitis B reactivation associated with immune-suppressive and biological therapies is
emerging to be an important cause of morbidity and mortality in patients with current or prior …

HBV reactivation (HBVr) can be prevented by nucleos (t) ide analogues (NAs). We
conducted a systematic review and meta-analysis on the risk of HBVr associated with new …

Correction - Gastroenterology Skip to Main Content Advertisement Gastroenterology American
Gastroenterological Association Home Articles & Issues Back Current Issue List of Issues …

INTRODUCTION—The natural course of hepatitis B virus (HBV) infection is determined
through the interplay between viral replication and the host's immune response. HBV …

Hepatitis B virus reactivation (HBVr) during and after immunosuppressive/
immunomodulatory (IS/IM) therapy is associated with significant morbidity and mortality …

Hepatitis B virus (HBV) reactivation in the setting of immunosuppressive therapy is an
increasingly recognized and preventable cause of elevated liver enzymes and clinical …

The proportion of hepatitis B virus (HBV) previously exposed patients who receive
immunosuppressive treatment is usually very small. However, if these individuals are …

Hepatitis B virus reactivation (HBVr) during immunosuppressive drug therapy is a serious
clinical disorder that can result in severe hepatitis, fulminant liver failure, and death. It occurs …

Patients with chronic HBV infection are at risk of reactivation of HBV should they require
immunosuppressive therapies for a variety of clinical settings, including chemotherapy for …